NCT02854488 | Study Connect

Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others.

* Required field

Your Email Address *

Please enter valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Recruiting

Yervoy Pregnancy Surveillance Study - CA184-487

Updated: 15 February, 2018 | ClinicalTrials.gov

About This Trial
Key Eligibility Criteria
Trial Site Locations

Print Friendly Summary

CONSIDERING THIS TRIAL?

Print this page and the trial guide to help you talk with your doctor.

Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Print this page CA184-487

Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

Gender(s)
N/A

Age Range
1

Location(s)
Recruiting

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Women Exposed to Yervoy (ipilimumab) During Pregnancy

Drug: Yervoy

Key Eligibility Criteria

Inclusion Criteria: - Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Exclusion Criteria: - Women whose ipilimumab exposure is outside the window of pregnancy exposure - Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?

Email Us